Intra-Cellular Therapies Inc
Closed
SectorHealthcare
0
Overview
Share price change
24h
Min
Max
Recommendations | Buy |
|---|---|
12 Months Forecast | -0.79% downside |
News Sentiment
By Acuity
50%
50%
155 / 345 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Intra-Cellular Therapies Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Intra-Cellular Therapies Inc Forecast
Price Target
By TipRanks
-0.79% downside
12 Months Forecast
Average 130.83 USD -0.79%
High 132 USD
Low 118 USD
Based on 13 Wall Street analysts offering 12 month price targets forIntra-Cellular Therapies Inc - Dist in the last 3 months.
Sentiment
By Acuity
155 / 345 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
